Coronary Artery Disease (CAD): A Cardiologist's Guide to Symptoms, Testing, and Treatment

I spend more time talking with patients about coronary artery disease than any other topic in my Encinitas cardiology practice. It remains the leading cause of death in the United States for both men and women, and the most common reason a patient ends up in my office. Yet most patients arrive with only a vague idea of what CAD actually is, how it develops, and what we can do about it. Some come in scared after a parent’s heart attack. Others find out by accident during an unrelated workup. A surprising number believe coronary artery disease is just part of getting old, something to accept rather than treat. That belief is wrong, and it is dangerous.

This article is the longer version of the conversation I have with every new CAD patient. By the end of it you should understand what is happening inside your arteries, what numbers and tests actually matter, and what the right next step is for someone in your situation.

What Is Coronary Artery Disease?

Coronary artery disease is the buildup of cholesterol-rich, inflammatory plaque inside the coronary arteries that feed blood to the heart muscle. As plaque accumulates over decades, it narrows the arterial channel and reduces the oxygen supply available to the heart, especially during exertion. When a plaque ruptures, a blood clot forms at the site and can completely block the artery within minutes. That’s a heart attack.

CAD is sometimes called coronary heart disease (CHD), ischemic heart disease, or atherosclerotic heart disease. They all refer to the same underlying process: atherosclerosis in the coronary tree. It affects roughly 20 million American adults and contributes to one in every five deaths in the United States. Its prevalence rises sharply with age and with poorly controlled cardiovascular risk factors.

Importantly, CAD is a systemic disease. The same atherosclerotic process that narrows coronary arteries also affects the carotids (causing stroke), the renal arteries (causing chronic kidney disease), the aorta (causing aneurysm), and the leg arteries (causing peripheral arterial disease). Treating CAD is therefore not a local problem. It is a whole-body problem, and that perspective shapes everything I do for these patients.

How Does Coronary Artery Disease Develop?

CAD develops through a four-step process that runs silently for decades: endothelial injury from hypertension, high LDL, diabetes, or smoking; infiltration of LDL into the arterial wall; recruitment of macrophages that engulf cholesterol and become foam cells; and progressive plaque growth driven by inflammation. Most patients have substantial disease years before the first symptom appears.

The healthy coronary artery has a smooth inner lining called the endothelium. Damage to this lining, from elevated blood pressure, circulating LDL cholesterol particles, glucose toxicity in diabetes, nicotine and combustion byproducts in smokers, or chronic inflammatory disease, sets the entire cascade in motion. Once the endothelium is injured, low-density lipoprotein (LDL) particles infiltrate beneath it and are taken up by infiltrating macrophages. The macrophages become engorged with cholesterol, transform into foam cells, and release inflammatory cytokines that recruit more immune cells, perpetuating the process.

Over years, this combination of cholesterol-loaded foam cells, smooth muscle proliferation, fibrous tissue deposition, and calcification produces a mature atherosclerotic plaque. Plaques are not all equally dangerous. Stable plaques have a thick fibrous cap, relatively low inflammatory activity, and grow predictably. They cause exertional symptoms when they reach roughly 70% stenosis. Vulnerable plaques have a thin fibrous cap, a large necrotic lipid core, and active inflammation. They rupture suddenly, often when they were less than 50–70% stenotic, exposing the thrombogenic core to the bloodstream and producing the clot that causes most heart attacks.

A 2023 JAMA Cardiology analysis confirmed that the majority of acute coronary syndromes arise from plaques that were not flow-limiting on prior imaging. This is the most important pathophysiologic fact in modern cardiology, because it tells us that fixing a single severe blockage (what stenting and bypass surgery do) does not protect the rest of the arterial tree. Only systemic medical therapy and aggressive risk-factor management do that.

What Are the Risk Factors for Coronary Artery Disease?

The major CAD risk factors fall into three buckets: modifiable risk factors (high LDL, high blood pressure, diabetes, tobacco use, obesity, physical inactivity, poor diet, chronic stress), non-modifiable risk factors (age, male sex, family history of premature CAD), and emerging risk factors (lipoprotein(a), metabolic syndrome, sleep apnea, chronic inflammatory disease, chronic kidney disease, clonal hematopoiesis). The lion’s share of cardiovascular risk is modifiable, which is the whole basis of preventive cardiology.

CAD Risk Factors at a Glance

The Pooled Cohort Equations (PCE) developed by the American College of Cardiology and the American Heart Association estimate 10-year ASCVD risk from age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive treatment status, diabetes status, and smoking. A 10-year risk of 7.5% or higher typically triggers statin therapy; risk below 5% generally favors lifestyle change alone unless emerging risk factors push the case higher.

Family history is more important than most patients realize. A father, brother, or son with CAD before age 55, or a mother, sister, or daughter before age 65, roughly doubles your own risk independent of other factors. Lipoprotein(a) is the most under-tested risk modifier in cardiology. About 20% of adults carry an elevated level that meaningfully raises CAD and aortic stenosis risk, and a one-time blood test settles the question for life.

What Are the Symptoms of Coronary Artery Disease?

The hallmark symptoms of CAD are exertional chest pressure or tightness that resolves with rest (stable angina) and shortness of breath on exertion. When a plaque ruptures, the picture changes to an acute coronary syndrome with chest pain at rest, sweating, nausea, and often pain radiating to the jaw, neck, shoulder, or arm. Women, older adults, and patients with diabetes are far more likely to present with atypical symptoms or no symptoms at all, which is why CAD is missed in those populations.

Stable angina is the most common chronic CAD symptom. It is typically a substernal pressure, tightness, or squeezing that comes on predictably with the same workload (walking up a flight of stairs, lifting something heavy, the first hill on a familiar walk) and resolves within minutes of stopping or with a sublingual nitroglycerin tablet. Patients often describe it as “discomfort” rather than “pain,” and many initially attribute the sensation to indigestion, anxiety, or being out of shape.

The dangerous end of the spectrum is acute coronary syndrome (ACS), which has three forms. ST-elevation myocardial infarction (STEMI) is a total occlusion of a coronary artery; the muscle downstream is actively dying and the ECG shows characteristic ST-segment elevation. STEMI is a true emergency requiring immediate cardiac catheterization for primary PCI within 90 minutes of first medical contact. Non-ST-elevation myocardial infarction (NSTEMI) is a partial occlusion with measurable heart muscle injury (elevated high-sensitivity troponin) but no full-thickness ECG changes. NSTEMI usually requires urgent catheterization within 24 hours. Unstable angina has the symptoms of NSTEMI without measurable troponin elevation; it is a warning that infarction may be imminent.

About 79% of men and 74% of women with ACS report chest discomfort, but 40–48% of patients have atypical presentations. These include isolated shortness of breath, indigestion-like discomfort, jaw or back pain, profound fatigue, lightheadedness, or syncope. Women, older adults, and patients with diabetes are over-represented in the atypical group. If something feels wrong, and especially if it correlates with exertion, I would rather see a patient in the office or the emergency room and rule out CAD than learn about it the hard way.

How Is Coronary Artery Disease Diagnosed?

For stable patients, CAD is diagnosed with a layered workup: estimate pretest probability from age, sex, and symptoms; then choose a non-invasive imaging test (CAC score, coronary CT angiography, or stress testing) appropriate to that probability; reserve invasive coronary angiography for high-risk findings or for patients being considered for revascularization. For acute presentations, ECG within 10 minutes and high-sensitivity troponin drive immediate decisions.

Non-Invasive Tests for Coronary Artery Disease

For most patients without symptoms but with elevated risk on the Pooled Cohort Equations, I now reach for CAC scoring as the single most useful test in preventive cardiology. It is inexpensive, requires no contrast, and directly visualizes the disease we’re trying to prevent. A CAC of 0 in a patient with borderline LDL can permit deferring statin therapy. A CAC of 200 in the same patient flips the conversation entirely. Statin is on board, and the LDL target drops to under 70 mg/dL.

For symptomatic patients with stable chest pain, the 2021 ACC/AHA Chest Pain Guideline has shifted strongly toward CCTA as the first-line test. CCTA visualizes both the lumen and the plaque, has excellent negative predictive value, and identifies non-flow-limiting atherosclerosis that would be missed by stress testing alone. The PROMISE trial showed that more than half of cardiovascular events arise from non-obstructive disease, exactly the population CCTA detects.

When I find moderate stenosis on invasive angiography, I almost always confirm functional significance with fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR). An FFR ≤ 0.80 or iFR ≤ 0.89 indicates a hemodynamically significant lesion worth stenting; above those thresholds, medical therapy is appropriate.

How Is Coronary Artery Disease Treated?

The foundation of CAD treatment is optimal medical therapy: high-intensity statin therapy targeting LDL below 70 mg/dL (below 55 in high-risk patients), blood pressure below 130/80 mmHg, antiplatelet therapy, smoking cessation, and lifestyle change. Revascularization with PCI or CABG is added for symptom control or for high-risk anatomy, not to improve outcomes in stable disease. This conclusion comes from the ISCHEMIA trial and the 2023 AHA/ACC chronic coronary disease guideline.

Coronary Artery Disease Treatment Targets

Lipid management is the cornerstone of CAD therapy and the single intervention with the largest mortality benefit. High-intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) is recommended for every patient with established CAD, targeting at least a 50% LDL reduction. Ezetimibe (IMPROVE-IT trial) adds another 15–20% LDL reduction and a 6% relative reduction in events. PCSK9 inhibitors (alirocumab, evolocumab) drop LDL another 50–60% and reduce cardiovascular events by 15% in FOURIER and ODYSSEY OUTCOMES. Inclisiran, a small interfering RNA targeting PCSK9 mRNA, is dosed twice yearly and a meaningful adherence advantage for patients who struggle with daily pills.

Antiplatelet therapy with aspirin 81 mg is standard for secondary prevention in established CAD. After a stent or heart attack, dual antiplatelet therapy (DAPT) combining aspirin with a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) is used for 3–12 months. The 2023 guidelines have shifted toward shorter DAPT durations (3–6 months) for many patients, particularly those at higher bleeding risk.

Diabetes management in CAD has been transformed by SGLT2 inhibitors and GLP-1 receptor agonists. Empagliflozin (EMPA-REG), dapagliflozin (DAPA-HF), semaglutide (SUSTAIN-6, SELECT), and dulaglutide (REWIND) all reduce major adverse cardiovascular events independently of their glucose effects. The 2023 chronic coronary disease guideline lists these agents as preferred for patients with CAD plus diabetes.

A major recent guideline change: long-term beta-blocker therapy is no longer recommended for stable CAD patients who have not had a heart attack within the past year and who have normal left ventricular function. For decades we treated every CAD patient with a beta-blocker indefinitely; that has changed.

Lifestyle interventions are not optional add-ons. The Mediterranean diet (PREDIMED), regular aerobic activity, resistance training, smoking cessation, weight optimization, and stress management each independently reduce cardiovascular events. Cardiac rehabilitation after a stent or heart attack reduces mortality by roughly 25% and is one of the most under-used interventions in cardiology.

What Did the ISCHEMIA Trial Show About CAD Treatment?

The ISCHEMIA trial randomized 5,179 patients with stable coronary disease and moderate-to-severe ischemia on stress testing to either an invasive strategy (cardiac catheterization plus revascularization) or a conservative strategy (optimal medical therapy alone, with catheterization reserved for medication failure). After 3.3 years, there was no difference in cardiovascular death, heart attack, or all-cause mortality between the two groups. The invasive strategy did provide better angina relief.

ISCHEMIA changed how cardiologists counsel patients with stable disease. The primary composite endpoint (cardiovascular death, MI, hospitalization for unstable angina, heart failure, or cardiac arrest) was 13.3% in the invasive arm versus 15.5% in the conservative arm (hazard ratio 0.93, 95% confidence interval 0.80–1.08). There was an early signal of more periprocedural MIs in the invasive arm and a later signal of fewer spontaneous MIs; the two roughly offset each other.

What invasive therapy did consistently provide was better angina control. Patients who underwent revascularization had greater improvement in chest pain symptoms at three months, and the benefit was sustained at three years. The benefit was largest in patients who had weekly or daily angina at baseline.

The practical implication is straightforward: if you have stable coronary disease, well-controlled symptoms, and good adherence to medical therapy, you can defer catheterization and stenting without sacrificing survival. If your angina is significantly affecting your quality of life despite medication, revascularization is a reasonable next step. The decision should be shared between you and your cardiologist, informed by your symptom burden, anatomy, and preferences.

PCI or CABG: Which Revascularization Strategy Is Right for You?

CABG is preferred for patients with left main disease and high SYNTAX score, complex multivessel disease (SYNTAX > 33), multivessel disease in diabetics (FREEDOM trial), and significantly reduced ejection fraction (LVEF ≤ 35%). PCI is reasonable for less complex anatomy, single-vessel disease, high surgical risk, and patient preference favoring a less invasive approach. The decision should be made by a multidisciplinary Heart Team, not by a single physician in isolation.

CABG’s unique advantage is field protection. A bypass graft is sewn downstream of the diseased segment, effectively shunting around future blockages that may develop upstream. PCI treats only the specific stenosis where the stent is placed; new blockages elsewhere in the same artery still occur. This is why long-term PCI patients have higher rates of repeat revascularization and spontaneous MI compared with CABG patients in complex disease.

For left main coronary artery disease with SYNTAX ≤ 33, PCI is non-inferior to CABG. For left main with SYNTAX > 33, CABG has significantly lower five-year mortality. For multivessel disease with SYNTAX > 33, CABG reduces 10-year mortality by approximately 40% compared with PCI. For diabetic patients with multivessel disease, the FREEDOM trial demonstrated a clear mortality benefit for CABG. For patients with LVEF ≤ 35%, CABG improves survival.

In older adults (75+), the calculus shifts toward individualized assessment of frailty, cognitive function, comorbidity burden, and life expectancy rather than anatomic complexity alone. A frail 82-year-old with multivessel disease may be better served by PCI even with a worse anatomic score, because the surgical recovery risk outweighs the long-term revascularization advantage.

What New Treatments Are Emerging for Coronary Artery Disease?

The most important recent additions to the CAD toolkit are low-dose colchicine for residual inflammatory risk (LoDoCo2, COLCOT), inclisiran for twice-yearly LDL lowering, icosapent ethyl for residual triglyceride risk (REDUCE-IT), and low-dose rivaroxaban 2.5 mg twice daily combined with aspirin for high-risk secondary prevention (COMPASS).

Colchicine at 0.5 mg daily was repurposed for CAD based on two landmark trials. The LoDoCo2 trial in 5,522 patients with stable CAD showed a 31% reduction in the primary composite endpoint over 28.6 months. The COLCOT trial in 4,745 patients within 30 days of a heart attack showed a 23% reduction in major adverse cardiovascular events. Both effects are comparable to or larger than what PCSK9 inhibitors provide, at a fraction of the cost. Colchicine is now FDA-approved for atherosclerotic cardiovascular disease and is most useful in patients with elevated high-sensitivity C-reactive protein (hsCRP > 2 mg/L) despite statin therapy.

Inclisiran is a small interfering RNA that silences PCSK9 production in the liver. It is administered subcutaneously every six months, a major adherence advantage over daily statins or biweekly PCSK9 monoclonal antibody injections. The ORION program demonstrated approximately 50% LDL reduction with no significant safety concerns.

Icosapent ethyl (REDUCE-IT) is a purified EPA omega-3 that reduced major adverse cardiovascular events by 25% in patients with established cardiovascular disease and elevated triglycerides (≥ 150 mg/dL) on a statin. The effect is independent of triglyceride lowering itself.

Low-dose rivaroxaban 2.5 mg twice daily combined with aspirin (COMPASS trial) reduces major cardiovascular events by 24% in patients with established CAD or PAD, at the cost of a modest increase in major bleeding. It is now approved for this indication.

Anti-inflammatory therapies beyond colchicine are in development. Canakinumab (interleukin-1β blocker) showed a 17% event reduction in the CANTOS trial but was not brought to market for CV indications. Ziltivekimab (IL-6 ligand inhibitor) is in Phase 3 trials in high-risk CV populations.

What Are Common Misconceptions About Coronary Artery Disease?

The most damaging misconceptions about CAD are: that you would know if you had a blockage; that a normal stress test rules out plaque; that a stent “fixes” coronary disease; and that bypass surgery cures it. All four are wrong, and each one leads to under-treatment.

“I’d know if I had a blockage.” Many patients with significant coronary disease have no symptoms at all until an event. The disease can progress silently for years. Patients with diabetes, who often have impaired pain perception, are particularly likely to have silent ischemia. Regular cardiovascular risk assessment is how we catch this disease before it announces itself.

“My stress test was normal, so my arteries are fine.” A normal stress test means that at the time of the test we did not detect flow-limiting ischemia. It does not mean your arteries are free of plaque. Most heart attacks happen in plaques that were not flow-limiting on prior testing. This is why CCTA and CAC scoring, which visualize plaque directly, have become so valuable.

“I need a stent to fix my blockage.” ISCHEMIA showed that for stable CAD, stenting does not reduce death or heart attack compared with optimal medical therapy. Stents excel at symptom relief when angina is uncontrolled with medication, and they are lifesaving in acute coronary syndromes. For stable disease, they are a symptom treatment, not a survival treatment.

“Once I have a stent, I’m fixed.” A stent treats one segment of one artery. Atherosclerosis is a diffuse disease affecting the entire arterial tree. Without aggressive risk-factor management, new lesions develop elsewhere. The stent protects a few centimeters of artery; statins, antiplatelets, blood pressure control, and lifestyle change protect the entire vascular system.

“Bypass surgery cures coronary disease.” CABG creates new conduits around blockages but does not stop the underlying atherosclerotic process. Without lifelong medical therapy and risk-factor control, bypass grafts narrow and the native arteries continue to develop new disease. Every post-CABG patient needs lifelong statin therapy, antiplatelet therapy, and lifestyle commitment.

What Should You Expect After a CAD Diagnosis?

Expect to manage CAD as a chronic, lifelong condition with medications, regular follow-up, and meaningful lifestyle change. The disease is not curable, but with the tools we have in 2026, the vast majority of patients live long, active, fulfilling lives. The single biggest determinant of outcome is consistent adherence to optimal medical therapy.

In my Encinitas practice, a typical post-diagnosis trajectory looks like this. The first visit focuses on understanding the diagnosis and writing a plan: a high-intensity statin, an ACE inhibitor or ARB if blood pressure is elevated, aspirin if not already on it, and a frank conversation about smoking, diet, and exercise. Lab work at six weeks confirms LDL is on target and the medication is tolerated.

Cardiac rehabilitation is enrolled within two months of any cardiac event. The structured exercise, education, and risk-factor coaching reduce mortality by about 25% over the years that follow, a benefit comparable to any single medication, often overlooked.

Follow-up after the initial stabilization is typically every six months for the first year, then annually for stable patients. We track LDL, hemoglobin A1c, blood pressure, and weight at each visit. We adjust medication based on response, side effects, and emerging evidence. We celebrate progress and address setbacks.

I see patients in my Encinitas practice who have lived twenty and thirty years with documented coronary artery disease, still active, still working, still traveling, still raising grandchildren. None of them got there by accident. They got there by treating the disease seriously, the medications, the lifestyle, the follow-up, over the long term.

Coronary Artery Disease: The Bottom Line

Coronary artery disease is the most common chronic cardiovascular condition in adults, and one of the most manageable. The single highest-leverage intervention is aggressive LDL lowering with a high-intensity statin (and PCSK9 inhibitor or inclisiran when needed) to push LDL below 70 mg/dL. The combination of optimal medical therapy, lifestyle change, and selective revascularization for the right anatomy or symptom burden has transformed CAD from a death sentence to a long-term partnership with a cardiologist.

If you have been told you have CAD, or you have risk factors and want to know where you stand, the highest-yield next steps are: get a fasting lipid panel and high-sensitivity troponin if you are symptomatic; get a one-time Lp(a) if you have never had it tested; consider a CAC score if you are an asymptomatic adult age 40–75 at intermediate risk; and schedule a focused visit with your cardiologist to build a written plan.

If you are in Encinitas or the broader San Diego area and looking for a cardiologist who will work through this in detail with you, I would be glad to help. Together we can build a strategy that protects your heart for the long term.

Frequently Asked Questions About Coronary Artery Disease

What is the difference between coronary artery disease and a heart attack?

Coronary artery disease is the underlying chronic process, plaque buildup in the heart’s arteries, that develops silently for decades. A heart attack (myocardial infarction) is an acute event that happens when a plaque ruptures and forms a blood clot that suddenly blocks one of those arteries. You can have CAD for years before any heart attack, and aggressive CAD treatment substantially reduces the chance one ever occurs.

Do I need a stent for stable CAD?

Usually no. The ISCHEMIA trial showed that for stable coronary disease, optimal medical therapy alone is as effective as stenting at preventing death and heart attack. Stents reliably improve symptoms when angina is not controlled with medication, and they are lifesaving in acute coronary syndromes. For stable disease, the right first move is aggressive medical therapy and lifestyle change.

Can coronary artery disease be reversed?

Plaque can be stabilized, inflammation can be reduced, and modest plaque regression has been demonstrated with intensive LDL lowering in trials like REVERSAL and ASTEROID. CAD cannot be made to disappear entirely, but with statin-driven LDL below 70 mg/dL, and even better below 55, the risk of future events drops dramatically and many patients live decades without recurrence.

What is the difference between PCI and CABG?

PCI (percutaneous coronary intervention, or stenting) is a catheter-based procedure in which a balloon-mounted stent props the artery open at the narrowing. CABG (coronary artery bypass grafting) is open-heart surgery in which a vein or artery from elsewhere in the body is sewn around the blockage. PCI has shorter recovery; CABG provides better long-term protection in complex multivessel disease, left main disease, diabetic patients, and patients with reduced ejection fraction.

How is CAD diagnosed without an invasive procedure?

Most CAD today is diagnosed non-invasively. Coronary CT angiography (CCTA) directly visualizes plaque and is the first-line test for symptomatic patients with low-to-intermediate pretest probability. Coronary artery calcium (CAC) scoring quantifies calcified plaque burden in asymptomatic patients. Stress testing (exercise ECG, stress echo, nuclear, or stress MRI) looks for functional evidence that a blockage is restricting blood flow. Invasive angiography is reserved for high-risk findings or planning revascularization.

Why do I need a statin if my LDL is already in the normal range?

The LDL value considered “normal” for the general population is too high for someone with established CAD. Guidelines call for LDL below 70 mg/dL for any patient with known coronary disease, and below 55 mg/dL for high-risk patients. Statins also have anti-inflammatory and plaque-stabilizing effects that go beyond cholesterol lowering. Almost every patient with CAD belongs on a statin regardless of their starting LDL.

What is the recovery time for bypass surgery versus a stent?

PCI recovery is typically 1–3 days in the hospital with return to most normal activities within 1–2 weeks. CABG involves a 4–7 day hospital stay and 6–12 weeks of full recovery, with cardiac rehabilitation in the second month critical for outcomes. Long-term, CABG patients in complex disease need fewer repeat procedures than PCI patients.

What does a high CAC score mean if I have no symptoms?

A high coronary artery calcium score means you have plaque in your coronary arteries even without symptoms. It does not by itself indicate that a specific blockage is restricting blood flow (many plaques are not flow-limiting), but it does identify you as someone at substantially higher risk of a future cardiovascular event. The right response is to escalate prevention: aggressive LDL lowering, blood pressure control, statin therapy regardless of LDL baseline, and consistent lifestyle change.

References

Stone, Peter H., Peter Libby, and William E. Boden. “Fundamental Pathobiology of Coronary Atherosclerosis and Clinical Implications for Chronic Ischemic Heart Disease Management: The Plaque Hypothesis.” JAMA Cardiology 8, no. 2 (2023): 192–201.

Joshi, Parag H., and James A. de Lemos. “Diagnosis and Management of Stable Angina: A Review.” JAMA 325, no. 17 (2021): 1765–1778.

Rao, Sunil V., Michelle L. O’Donoghue, Marc Ruel, et al. “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.” Journal of the American College of Cardiology 85, no. 15 (2025): 1–98.

Virani, Salim S., Lori K. Newby, Suzanne V. Arnold, et al. “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease.” Journal of the American College of Cardiology 82, no. 9 (2023): 833–955.

Gulati, Martha, Phillip D. Levy, Debabrata Mukherjee, et al. “2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain.” Journal of the American College of Cardiology 78, no. 22 (2021): e187–e285.

Maron, David J., Judith S. Hochman, Harmony R. Reynolds, et al. “Initial Invasive or Conservative Strategy for Stable Coronary Disease (ISCHEMIA).” New England Journal of Medicine 382, no. 15 (2020): 1395–1407.

Nidorf, Stefan M., Aernoud T. Fiolet, Arend Mosterd, et al. “Colchicine in Patients with Chronic Coronary Disease (LoDoCo2).” New England Journal of Medicine 383, no. 19 (2020): 1838–1847.

Tardif, Jean-Claude, Simon Kouz, David D. Waters, et al. “Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction (COLCOT).” New England Journal of Medicine 381, no. 26 (2019): 2497–2505.

Ridker, Paul M., Deepak L. Bhatt, Aruna D. Pradhan, et al. “Inflammation and Cholesterol as Predictors of Cardiovascular Events Among Patients Receiving Statin Therapy: A Collaborative Analysis of Three Randomised Trials.” Lancet 401, no. 10384 (2023): 1293–1301.

Sabatine, Marc S., Robert P. Giugliano, Anthony C. Keech, et al. “Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER).” New England Journal of Medicine 376, no. 18 (2017): 1713–1722.

Schwartz, Gregory G., P. Gabriel Steg, Michael Szarek, et al. “Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (ODYSSEY OUTCOMES).” New England Journal of Medicine 379, no. 22 (2018): 2097–2107.

Bhatt, Deepak L., P. Gabriel Steg, Michael Miller, et al. “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT).” New England Journal of Medicine 380, no. 1 (2019): 11–22.

Eikelboom, John W., Stuart J. Connolly, Jackie Bosch, et al. “Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (COMPASS).” New England Journal of Medicine 377, no. 14 (2017): 1319–1330.